Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202867 | 0.79 | PREP (0.47) | PREPFKBP1AGFERALDH1A1NPSR1 | |
| SCHEMBL10844332 | 0.79 | PREP (0.55) | PREPKMT2AFAPFKBP1AHSD17B10 | |
| SCHEMBL5528936 | 0.77 | PREP (0.54) | PREPKMT2AFKBP1ACYP3A4CYP2C9 | |
| SCHEMBL12272394 | 0.76 | PREP (0.66) | PREPKMT2AFKBP1ACYP3A4CYP2C9 | |
| SCHEMBL11033242 | 0.75 | PREP (0.68) | PREPKMT2AFKBP1ACYP3A4ACE | |
| SCHEMBL11764594 | 0.75 | PREP (0.71) | PREPKMT2AFKBP1AACEALDH1A1 | |
| SCHEMBL2228388 | 0.75 | PREP (0.71) | PREPKMT2AFKBP1AACEALDH1A1 | |
| SCHEMBL5264694 | 0.75 | PREP (0.55) | PREPKMT2AGFERHSD17B10ACE | |
| SCHEMBL28583418 | 0.75 | PREP (0.65) | PREPKMT2AFKBP1ACYP3A4CYP2C9 | |
| SCHEMBL9536494 | 0.75 | PREP (0.47) | PREPFAPFKBP1AGFERACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | PREP 1075/4885KMT2A 1108/4885FAP 2689/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | PREP 1392/4885KMT2A 2353/4885FAP 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.